Business Context and Reporting Period
This Form 8-K is a current report filed by Leap Therapeutics, Inc. (noting a discrepancy in the request metadata which listed "Cypherpunk Technologies Inc.") on June 18, 2020. The registrant is a Delaware corporation with its principal executive offices in Cambridge, MA, and its common stock trades on the Nasdaq Global Market under the symbol LPTX. The filing reports the entry into a material definitive agreement regarding a public offering.
Key Financial Metrics and Transaction Details
The filing details an underwritten public offering with the following financial parameters:
- Common Stock Issuance: 20,250,000 shares at a public offering price of $2.00 per share.
- Pre-Funded Warrants: 2,250,000 warrants to purchase common stock at a price of $1.999 per warrant.
- Underwriters' Option: An option to purchase up to an additional 3,375,000 shares of common stock at $2.00 per share, exercisable for 30 days.
- Expected Net Proceeds: Approximately $41,797,750, assuming no exercise of the underwriters' option and after deducting discounts, commissions, and estimated expenses.
- Closing Date: Expected on June 22, 2020, subject to customary conditions.
The filing does not provide historical revenue, profit, cash flow, margin, or debt figures, as this is a transactional report rather than a periodic financial statement.
Material Changes and Use of Proceeds
The primary material change is the execution of the underwriting agreement to raise capital. The Company intends to use the net proceeds for general corporate purposes, specifically including:
- Funding clinical trials of its candidate drug, DKN-01.
- Manufacturing of clinical trial material.
- Working capital and general and administrative expenses.
Guidance, Risks, and Unusual Items
Management Commentary and Lock-Up: As part of the agreement, certain officers and directors agreed to a lock-up period, refraining from selling or disposing of common stock for 90 days following the date of the final prospectus supplement, subject to exceptions and written consent from Piper Sandler & Co.
Risks and Contingencies: The transaction is subject to customary closing conditions. The Pre-Funded Warrants do not carry voting rights or other privileges of common stock until exercised. The filing incorporates by reference the full Underwriting Agreement and legal opinions, noting that representations and warranties are subject to limitations and confidential disclosures.
Investor Verification Checklist
- Verify the final closing date of the offering (expected June 22, 2020) and whether the underwriters' option was exercised.
- Confirm the actual net proceeds received after all expenses, as the $41.8 million figure is an estimate.
- Review the final prospectus supplement for any changes to the use of proceeds or risk factors.
- Monitor the progress of the DKN-01 clinical trials funded by this capital raise.
- Check for any subsequent filings regarding the exercise of the Pre-Funded Warrants.